Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab

Jacqueline K. Suen, Linda Bressler, Stacy S. Shord, Michael Warso, John Lee Villano

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


Cetuximab (Erbitux) is a recombinant, chimeric monoclonal antibody that binds with high affinity to the extracellular ligand-binding domain of human epidermal growth factor receptor. We report a case of repeated responses to cetuximab in a patient with nonresectable squamous cell skin cancer having strong human epidermal growth factor receptor expression. Nonmelanoma skin cancer is the most common cancer in the US, with more than 1 million new cases detected annually, of which 20-25% are squamous cell carcinomas. Although most primary cutaneous squamous cell carcinomas have a high clinical cure rate and are easily treated, the small subset of cancers that recur or metastasize has a poor prognosis, and accounts for approximately 2000 deaths per year. Treatment with cetuximab should be considered for human epidermal growth factor receptor expressing tumors in a palliative setting.

Original languageEnglish
Pages (from-to)827-829
Number of pages3
JournalAnti-Cancer Drugs
Issue number7
StatePublished - Aug 2007


  • Cetuximab
  • Cutaneous
  • Human epidermal growth factor
  • Skin cancer
  • Squamous cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research


Dive into the research topics of 'Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab'. Together they form a unique fingerprint.

Cite this